Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
24.16
-0.83 (-3.32%)
May 8, 2026, 4:00 PM EDT - Market closed

Damora Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts that cover Damora Therapeutics stock have a consensus rating of "Buy" and an average price target of $43, which forecasts a 77.98% increase in the stock price over the next year. The lowest target is $40 and the highest is $46.

Price Target: $43 (+77.98%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$40$43$46$46
Change+65.56%+77.98%+90.40%+90.40%

Analyst Ratings

The average analyst rating for Damora Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingApr '26May '26
Strong Buy00
Buy22
Hold00
Sell00
Strong Sell00
Total22

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
RBC Capital
RBC Capital
Buy
Initiates
$40
BuyInitiates$40+65.56%Apr 24, 2026
Evercore ISI Group
Evercore ISI Group
Buy
Initiates
$46
BuyInitiates$46+90.40%Mar 25, 2026

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.55
from -153.95
EPS Next Year
-1.92
from -1.55
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
-------
Revenue Growth
-------
EPS
-51.22-60.63-36.08-18.53-153.95-1.55-1.92
EPS Growth
-------
Forward PE
-------
No. Analysts
-----77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027202820292030203120322033
Highn/an/a
Avgn/an/a
Lown/an/a

Revenue Growth

Revenue Growth20262027202820292030203120322033
High--
Avg--
Low--

EPS Forecast

EPS202620272028
High-1.00-1.43
Avg-1.55-1.92
Low-2.30-2.39

EPS Growth

EPS Growth202620272028
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.